WithdrawnInterventionalNot ApplicableUpdated May 14, 2020
Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection | NCT02933905 | Trialant
CompletedObservationalUpdated Oct 18, 2016
Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection
ClinicalTrials.gov ID
NCT02933905
Lead Sponsor
Fundació Institut Germans Trias i PujolOTHER
Overall Status
Completed
Study Type
Observational
Enrollment
38Actual
Last Update Posted
Oct 18, 2016Estimated
Start Date
Jan 2014
Primary Completion Date
Jan 2015Actual
Completion Date
Jun 2016Actual
Brief Summary
Influence of the vitreomacular interface on the progression of diabetic macular edema after treatment with intravitreal injection of vascular endothelial growth factor inhibitors
Diabetic Macular Edema
Vitreomacular Interface
Anti-VEGF Treatment
Intravitreal Ranibizumab injection
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diabetic macular edema treatable with antiangiogenic drugs
Exclusion Criteria:
age under 18
cardiovascular events during the last year
previous vitrectomy
previous macular edema treatment during the last 4 months